UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): MARCH 9, 2004
VASO ACTIVE PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
DELAWARE 001-31925 02-0670926
(State or other jurisdiction (Commission File No.) (IRS Employer
of incorporation No.) Identification No.)
99 ROSEWOOD DRIVE, SUITE 260, DANVERS, MASSACHUSETTS 01923
(Address of principal executive offices including zip code)
(978) 750-0090
(Registrant's telephone number, including area code)
TABLE OF CONTENTS
ITEM 5. OTHER EVENTS
ITEM 7. EXHIBITS
SIGNATURE
EXHIBIT 99.1 - PRESS RELEASE
2
- --------------------------------------------------------------------------------
ITEM 5. OTHER EVENTS
On March 9, 2004, Vaso Active Pharmaceuticals, Inc. (the "Company") issued a
press release in response to an article written by Matthew Goldstein that
appeared online in TheStreet.com on March 9, 2004. A copy of the press release
is attached as Exhibit 99.1.
ITEM 7. EXHIBITS
(c) EXHIBITS.
Exhibit 99.1 - Press Release, dated March 9, 2004.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
VASO ACTIVE PHARMACEUTICALS, INC.
By: /s/ John J. Masiz
---------------------------
Name: John J. Masiz
Title: President, CEO
Date: March 10, 2004
3